# A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy

> **NCT00109265** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Erlotinib HCl (OSI-774)

## Key facts

- **NCT ID:** NCT00109265
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** —
- **Final completion:** 2002-10
- **Target enrollment:** — (—)
- **Last updated:** 2015-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00109265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00109265, "A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00109265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*